This was an open-label study. It evaluated the renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild, or the "quad" pill) and cobicistat. For those patients with mild-to-moderate renal impairment (estimated glomerular filtration rate [eGFR]: 50 to <90 mL/min).